# +ND Capital

> +ND Capital is a VC fund in San Mateo backing Biotechnology and Health Care. See 68 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Mateo, United States
- Total investments: 68
- Last investment: Apr 2026
- Lead investor: 31%
- Fund size: $335M
- Last fund: May 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nanodimension/
- X (Twitter): https://www.twitter.com/nanodimension
- Website: https://nd.capital/

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

## Contacts

5 contacts available for +ND Capital. Shizune tracks 9 team members at +ND Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nd-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $10M–$60M |
| Series B | $13M–$100M |
| Series C | $12M–$67M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 21 | 31% |
| Health Care | 16 | 24% |
| Medical | 10 | 15% |
| Therapeutics | 7 | 10% |
| Pharmaceutical | 7 | 10% |

42 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 14 | 21% |
| Series A | 10 | 15% |
| Series C | 10 | 15% |
| Series D | 7 | 10% |
| Funding Round | 7 | 10% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 23 | 34% |
| Switzerland | 4 | 6% |
| United Kingdom | 3 | 4% |
| Denmark | 2 | 3% |
| Canada | 1 | 1% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aymeric Sallin | Founder and CEO | 21 | https://shizune.co/investors/profile/aymeric-sallin |
| Eric Moessinger | Partner | 22 | https://shizune.co/investors/profile/eric-moessinger |
| Jonathan Nicholson | Director | 0 | https://shizune.co/investors/profile/jonathan-nicholson |
| Kirill Kuzmichev | Principal | 0 | https://shizune.co/investors/profile/kirill-kuzmichev |
| Louis-Philippe Lalonde | Entrepreneur-In-Residence | 0 | https://shizune.co/investors/profile/louis-philippe-lalonde-fab9 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lightcast Discovery | Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $27M | Venture - Series Unknown | Apr 14, 2026 |  |
| SPARK Microsystems | SPARK Microsystems is a fabless semiconductor company that is leading the way towards ultra-low power wireless communications for the Internet of Things revolution. With its patented technologies, SPARK Microsystems will bring to market a high performance wireless transceiver that allows for orders of magnitude improved power consumption andlatency while providing higher data rates than competing technologies. For more information, please visit www.sparkmicro.com. | $12.4M | Series B | Mar 23, 2026 |  |
| Syndex Bio | Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease. | $15.5M | Seed | Feb 23, 2026 |  |
| Visby Medical | Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $55M | Venture - Series Unknown | Jun 17, 2025 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M | Series A | May 08, 2025 |  |
| AIRNA | AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $155M | Series B | Apr 01, 2025 |  |
| Constructive Bio | Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | $57.7M | Series A | Sep 24, 2024 |  |
| Vandria | Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. | $10.1M | Series A | Aug 21, 2024 |  |
| AIRNA | AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $60M | Series A | Jul 31, 2024 |  |
| PulseSight Therapeutics | PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness. |  | Seed | Feb 28, 2024 |  |

10 of 68 investments shown.

## Co-investors
- [NanoDimension](https://shizune.co/investors/profile/nanodimension) — VC Fund, 42 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 9 deals together
- [Paladin Capital Group](https://shizune.co/investors/profile/paladin-capital-group) — VC Fund, 8 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 7 deals together
- [Illumina Ventures](https://shizune.co/investors/profile/illumina-ventures) — VC Fund, 5 deals together
- [Mérieux Equity Partners](https://shizune.co/investors/profile/merieux-equity-partners) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Manufacturing Investors in Switzerland](https://shizune.co/investors/manufacturing-investors-switzerland)
- [Manufacturing VC Funds in Switzerland](https://shizune.co/investors/manufacturing-vc-funds-switzerland)
- [Climate Investors in Switzerland](https://shizune.co/investors/climate-investors-switzerland)
- [Climate VC Funds in Switzerland](https://shizune.co/investors/climate-vc-funds-switzerland)
- [Biotechnology Investors in Denmark](https://shizune.co/investors/biotechnology-investors-denmark)
- [Biotechnology VC Funds in Denmark](https://shizune.co/investors/biotechnology-vc-funds-denmark)

## FAQ

### What does +ND Capital invest in?

+ND Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 68 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is +ND Capital's check size?

+ND Capital typically joins rounds of $10M–$60M at Series A, $13M–$100M at Series B and $12M–$67M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds +ND Capital participates in.

### How do I contact +ND Capital?

Public channels for +ND Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at +ND Capital?

The team at +ND Capital includes Aymeric Sallin (Founder and CEO), Eric Moessinger (Partner) and Jonathan Nicholson (Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co